Comments to the Food and Drug Administration (FDA) on the Draft Guidance for Industry, Clinical Laboratories, and FDA Staff on In Vitro Diagnostic Multivariate Index Assays (IVDMIAs)

Issued on July 26, 2007

Dear Sir or Madam:

Thank you for accepting comments in response to the revised draft guidance on In Vitro Diagnostic Multivariate Index Assays (“Guidance”). These comments represent a consumer/patient/advocate perspective, crafted by Genetic Alliance. Genetic Alliance is a coalition of more than 650 disease-specific advocacy organizations.

We appreciate the extension to the comment period.

We submitted comments on the first draft guidance and believe that most of them are still relevant.

We recently convened a genetic testing summit called Eyes on the Prize: Truth Telling about Genetic Testing. It was clear that this was a much needed forum, and more dialogue is needed and so we ask that FDA and the Department of Health and Human Services (HHS) convene public meetings to invite all stakeholders to dialogue about effective and efficient approaches to meet the common objective to assure quality and innovation in advanced diagnostic testing.

We recommend:

A clear definition of IVDMIAs. This is not a term found in the FFDCA. The second guidance does not define these tests unequivocally. In fact, the second guidance removed the term ‘in vitro assay’ and may in fact apply to many more tests than are intended.

A clear distinction between laboratory-developed tests (LDTs) that will be subject to FDA regulation as medical devices under the IVDMA policy and those that will not. Laboratories need certainty in order to develop diagnostics that have a clear regulatory pathway.

The 2007 Draft Guidance focuses on derivation or verification by the end-user. The end-user for IVDMIAs is generally the treating physician. We think that it is unrealistic to expect the treating physician to engage in derivation or verification. Instead, laboratory physicians and scientists already take the lead, as required by CLIA, in assuring analytic validity and providing consultations to clinicians about proper use of each test. In fact, it is our recommendation that the regulatory system acknowledge the increasing complexity of diagnostics in the realm of personalized medicine, and the need for access to these quality tests by healthcare professionals.
We agree that tests should be subject to transparency, and recommend that when test development and validation is transparent, they not be subjected to burdensome regulation that will limit their access and/or their ability to be improved iteratively as new information is acquired.

Further, FDA in collaboration with CMS should provide a clear distinction as to whether a test is subject to regulatory requirements under the Federal Food, Drug and Cosmetic Act (FFDCA) or CLIA. The 2007 Draft Guidance indicates that the device includes “all elements necessary for obtaining the result.” This overlaps CLIA’s domain and will create confusion for the labs being subjected to the two regulatory regimes.

FDA should allow a reasonable transition period following publication of any final policy on regulation of IVDMIAs to allow laboratories to come into compliance with the substantial new regulatory burdens that would be imposed, and FDA should not require laboratories to label IVDMIAs as “Investigational Use Only” during such a transition period.

FDA regulation should allow for clearance/approval of clinically meaningful intended use claims under the least burdensome means. Requiring limitations on intended use claims against use in treatment selection can render a test of little clinical usefulness to physicians or their patients and will result in payer denials of the test as “not medically necessary.”

Finally, and of great significance to our community is the intent of the guidance to regulate tests applying the Humanitarian Use Device definition. This is unacceptable, since HUD applies to devices for conditions that affect fewer than 4,000 people in the United States. The rare disease community uses the Orphan Drug Act definition: an orphan or rare disease is considered to have a prevalence of fewer than 200,000 affected individuals in the United States. There are more than 7,000 rare diseases, for which more than 1,300 genetic tests are currently available. The number of tests increases dramatically every year. The complexity of these tests will also increase dramatically as various gene interactions are understood and single gene disorder are understood in terms of a primary gene and multiple modifying genes, all of which need to be measured for prognosis, genotype/phenotype correlations and treatment decisions. As personalized medicine progresses, and genetic and genomic tests differentiate common conditions into thousands of conditions, all diseases will be ‘rare’ and need the special considerations of the orphan drug act. This is the standard that should be applied to tests.

Please give all of these recommendations serious consideration. We are the men, women and children whose lives hang in the balance as FDA attempts to apply the best regulatory paradigm to IVDMIAs. It is time that the regulatory schema enhances and in fact supports access to quality diagnostics in a thoughtful and clear manner. The right balance will support innovation and accelerate the development of the diagnostics we so desperately need.
Please feel free to contact us for further clarification or information.

Sincerely yours,

Sharon F. Terry
President & CEO

Organizations

Alpha-1 Advocacy Alliance
Ann Marie Benzinger
Wolftown, VA

American Sleep Apnea Association
Edward Grandi
Washington, DC

ARPKD/CHF Alliance
Colleen Zak
Kirkwood, PA

AviaraDx, Inc.
Mary Barry, CLS, MT(ASCP), MBA, Vice President, Clinical Laboratory Operations
Carlsbad, CA

BayBio
Chris Draper
South San Francisco, CA

BCCNS Life Support Network
Kristi Schmitt Burr, Executive Director
Burton, Ohio

C3: Colorectal Cancer Coalition
Carlea Bauman, President
Alexandria, VA

CADASIL Together We Have Hope
Billie Duncan-Smith, Director
Round Rock, TX
CardioDx
David Levison
Palo Alto, CA

CARES Foundation, Inc.
Gretchen Alger Lin, Public Affairs
Union, NJ

Claire Altman Heine Foundation, Inc.
Deborah Heine
Santa Monica, CA

Coalition of Heritable Disorders of Connective Tissue
Priscilla Cicarrilo, Co-President
Washington, DC

Cutaneous Lymphoma Foundation
Judy Jones
Birmingham, MI

Cutis Laxa Internationale
Marie-Claude Boiteux
France

Friedreich's Ataxia Research Alliance
Ronald J. Bartek, President
Springfield, VA

GeneDx, Inc.
Sherri J. Bale, Ph.D., F.A.C.M.G., President and Clinical Director
Gaithersburg, MD

Genetic Alliance BioBank
Sharon F. Terry, MA, President
Washington, DC

Genomic Health
Randy Scott, CEO
Redwood City, CA

Hypertrophic Cardiomyopathy Association
Lisa Salberg, President
Hibernia, NJ

In Need of Diagnosis, Inc.
Marianne Genetti, Executive Director
Orlando, FL
KS&A
Robert H. Shelton, Chairman, Board of Directors
Coto de Caza, CA

Kids With Heart National Association for Children’s Heart Disorders, Inc.
Michelle L. Rintamaki
Green Bay WI

MLD Foundation
Dean Suhr, President
West Linn, OR

Monogram Biosciences, Inc.
William D. Young, Chairman & CEO
South San Francisco, CA

National Fabry Disease Foundation
Jerry Walter, President and CEO
Washington, DC

National Foundation for Ectodermal Dysplasia
Mary K. Richter, Executive Director
Mascoutah, IL

National Tay-Sachs & Allied Diseases Association, Inc.
Kim Crawford
Boston, MA

Northeast Velo Cardio Facial Syndrome Support
Lisa Jennings
Weymouth, MA

Ovarian Cancer National Alliance
Cara Tenenbaum, Esq., Policy Director
Washington, DC

Patient's Best Friend
Suzanne Gauvreau, Founder
Harrison Township, MI

Periodic Paralysis Association
Benita Saatvedt
Columbia City, Oregon

The PKD Foundation
Dan Lara
Kansas City, Missouri
The Praxis Project
Makani Thembwa-Nixon
Washington, DC

Project DOCC - Delivery of Chronic Care
Maggie Hoffman, Director
Great Neck, NY

Pull-thru Network, Inc
Bonnie B. McElroy, Executive Director
Hoover, AL

PXE International
Sharon F. Terry, MA, Executive Director
Washington, DC

Quest Diagnostics
Jeanne M. Meck, PhD, Technical Director, Cytogenetics Laboratory
Chantilly, VA

Research Advocacy Network
Elda Railey and Mary Lou Smith, Co-founders
Plano, TX

SADS Foundation
Alice Lara, Director
Salt Lake City, UT

Save Babies Through Screening Foundation
Jill Levy-Fisch, President
Scarsdale, NY

Shwachman Diamond Syndrome Foundation
Blair Van Brunt
Grand Junction, CO

Sirius Genomics
Brad Popovich, MSc, PhD, FACMG, President and Chief Executive Officer
Vancouver, BC

Target Discovery, Inc.
Jeffrey N. Peterson, CEO
Palo Alto, CA

The Praxis Project
Makani Thembwa-Nixon
Washington, DC
VHL Family Alliance  
Camron King  
Sacramento, CA

Y-ME National Breast Cancer Organization  
Kay Wissmann, Director of Government Relations  
Chicago, IL

Individuals

Tiffany Amalfi  
Strong Memorial Hospital  
Pediatric Genetics Social Worker  
Rochester, NY

R. Stephen S. Amato, MD, PhD  
Director Medical Genetics Program  
Eastern Maine Medical Center  
Clinical Professor, Tufts University College Of Medicine  
Boston, MA

Elizabeth Berry-Kravis, MD, PhD  
Associate Professor of Pediatrics, Biochemistry, Neurology  
Rush University Medical Center  
Chicago, IL

Neil Buist, MD  
Professor Emeritus  
Oregon Health and Sciences University  
Portland, OR

Carol Christianson  
Jamestown, NC

Delia Clayton  
PXE International  
Washington, DC

Wendy DiNonno  
Eastern Virginia Medical School  
Newport News, VA

Lynn Dowling  
Greenbrae, CA
Celeste Gebauer  
Oakdale, MN

Pam Gerrol  
Brigham & Women's Hospital  
Boston, MA

Margaret L. Gulley, MD  
University of North Carolina  
Chapel Hill, NC

Lisa R. Leslie  
Baumgartner Insurance Agency  
Roseville, MN

Elizabeth Sampson  
Longmeadow, MA

Kathleen Sparbel PhD, APRN, BC  
Postdoctoral Fellow in Clinical Genetics  
University of Iowa College of Nursing  
Moline, IL

Susan Winter, MD, FAAP, FACMG  
Children's Hospital Central CA  
Madera, CA

Kathy Zeitz, JD  
Surprise, AZ